Literature DB >> 10992532

Incidence and causes of non-invasive mechanical ventilation failure after initial success.

M Moretti1, C Cilione, A Tampieri, C Fracchia, A Marchioni, S Nava.   

Abstract

BACKGROUND: The rate of failure of non-invasive mechanical ventilation (NIMV) in patients with chronic obstructive pulmonary disease (COPD) with acute respiratory insufficiency ranges from 5% to 40%. Most of the studies report an incidence of "late failure" (after >48 hours of NIMV) of about 10-20%. The recognition of this subset of patients is critical because prolonged application of NIMV may unduly delay the time of intubation.
METHODS: In this multicentre study the primary aims were to assess the rate of "late NIMV failure" and possible associated predictive factors; secondary aims of the study were evaluation of the best ventilatory strategy in this subset of patients and their outcomes in and out of hospital. The study was performed in two respiratory intensive care units (ICUs) on patients with COPD admitted with an episode of hypercapnic respiratory failure (mean (SD) pH 7.23 (0.07), PaCO(2) 85.3 (15.8) mm Hg).
RESULTS: One hundred and thirty seven patients initially responded to NIMV in terms of objective (arterial blood gas tensions) and subjective improvement. After 8.4 (2.8) days of NIMV 31 patients (23%; 95% confidence interval (CI) 18 to 33) experienced a new episode of acute respiratory failure while still ventilated. The occurrence of "late NIMV failure" was significantly associated with functional limitations (ADL scale) before admission to the respiratory ICU, the presence of medical complications (particularly hyperglycaemia), and a lower pH on admission. Depending on their willingness or not to be intubated, the patients received invasive ventilation (n=19) or "more aggressive" (more hours/day) NIMV (n=12). Eleven (92%) of those in this latter subgroup died while in the respiratory ICU compared with 10 (53%) of the patients receiving invasive ventilation. The overall 90 day mortality was 21% and, after discharge from hospital, was similar in the "late NIMV failure" group and in patients who did not experience a second episode of acute respiratory failure.
CONCLUSIONS: The chance of COPD patients with acute respiratory failure having a second episode of acute respiratory failure after an initial (first 48 hours) successful response to NIMV is about 20%. This event is more likely to occur in patients with more severe functional and clinical disease who have more complications at the time of admission to the ICU. These patients have a very poor in-hospital prognosis, especially if NIMV is continued rather than prompt initiation of invasive ventilation.

Entities:  

Mesh:

Year:  2000        PMID: 10992532      PMCID: PMC1745609          DOI: 10.1136/thorax.55.10.819

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

1.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

2.  Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients.

Authors:  A Torres; R Aznar; J M Gatell; P Jiménez; J González; A Ferrer; R Celis; R Rodriguez-Roisin
Journal:  Am Rev Respir Dis       Date:  1990-09

3.  Does noninvasive ventilation reduce the ICU nosocomial infection risk? A prospective clinical survey.

Authors:  K Nourdine; P Combes; M J Carton; P Beuret; A Cannamela; J C Ducreux
Journal:  Intensive Care Med       Date:  1999-06       Impact factor: 17.440

4.  Non-invasive modalities of positive pressure ventilation improve the outcome of acute exacerbations in COLD patients.

Authors:  M Vitacca; F Rubini; K Foglio; S Scalvini; S Nava; N Ambrosino
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease.

Authors:  J Bott; M P Carroll; J H Conway; S E Keilty; E M Ward; A M Brown; E A Paul; M W Elliott; R C Godfrey; J A Wedzicha; J Moxham
Journal:  Lancet       Date:  1993-06-19       Impact factor: 79.321

6.  Prevalence and severity of neurologic dysfunction in critically ill patients. Influence on need for continued mechanical ventilation.

Authors:  B J Kelly; M A Matthay
Journal:  Chest       Date:  1993-12       Impact factor: 9.410

7.  Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia.

Authors:  G U Meduri; G L Mauldin; R G Wunderink; K V Leeper; C B Jones; E Tolley; G Mayhall
Journal:  Chest       Date:  1994-07       Impact factor: 9.410

8.  Noninvasive face mask mechanical ventilation in patients with acute hypercapnic respiratory failure.

Authors:  G U Meduri; N Abou-Shala; R C Fox; C B Jones; K V Leeper; R G Wunderink
Journal:  Chest       Date:  1991-08       Impact factor: 9.410

9.  Nasal mask ventilation in acute respiratory failure. Experience in elderly patients.

Authors:  D Benhamou; C Girault; C Faure; F Portier; J F Muir
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

10.  Arterial oxygenation does not predict the outcome of patients with acute respiratory failure needing mechanical ventilation.

Authors:  P Jiménez; A Torres; J Roca; A Cobos; R Rodriguez-Roisin
Journal:  Eur Respir J       Date:  1994-04       Impact factor: 16.671

View more
  59 in total

Review 1.  Ethics and decision making in end stage lung disease.

Authors:  A K Simonds
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 2.  Hyperglycaemia in the acute care setting.

Authors:  Anjali Balasanthiran; Ben Zalin; Emma H Baker; Kevin Shotliff
Journal:  Clin Med (Lond)       Date:  2012-06       Impact factor: 2.659

3.  Early failure of noninvasive ventilation in chronic obstructive pulmonary disease with acute hypercapnic respiratory failure.

Authors:  Byuk Sung Ko; Shin Ahn; Kyung Soo Lim; Won Young Kim; Yoon-Seon Lee; Jae Ho Lee
Journal:  Intern Emerg Med       Date:  2015-09-04       Impact factor: 3.397

4.  [Noninvasive ventilation in acute respiratory insufficiency].

Authors:  C G Cornelissen; M Dreher
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-01-08       Impact factor: 0.840

5.  Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease.

Authors:  E H Baker; C H Janaway; B J Philips; A L Brennan; D L Baines; D M Wood; P W Jones
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

6.  Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008.

Authors:  Divay Chandra; Jason A Stamm; Brian Taylor; Rose Mary Ramos; Lewis Satterwhite; Jerry A Krishnan; David Mannino; Frank C Sciurba; Fernando Holguín
Journal:  Am J Respir Crit Care Med       Date:  2011-10-20       Impact factor: 21.405

7.  Noninvasive and invasive positive pressure ventilation for acute respiratory failure in critically ill patients: a comparative cohort study.

Authors:  Annelijn M Meeder; Dave H T Tjan; Arthur R H van Zanten
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 8.  [Hypercapnic respiratory failure. Pathophysiology, indications for mechanical ventilation and management].

Authors:  U Kreppein; P Litterst; M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-02-22       Impact factor: 0.840

9.  [Evidence-based medicine: implications from the guideline "non-invasive ventilation" in critically ill elderly patients].

Authors:  H J Heppner; K Singler; C C Sieber; M Christ; F Heirler; B Schönhofer
Journal:  Z Gerontol Geriatr       Date:  2011-04       Impact factor: 1.281

10.  Co-morbidity and acute decompensations of COPD requiring non-invasive positive-pressure ventilation.

Authors:  Raffaele Scala; Sandra Bartolucci; Mario Naldi; Marcello Rossi; Mark W Elliott
Journal:  Intensive Care Med       Date:  2004-07-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.